Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet
twitter: 4 X users

guideline: 2 clinical guideline sources

Readers on

mendeley: 94 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 18,240 followers.

Cemiplimab ph2 trial for metastatic/advanced pts found that in responders, 88% still had response at 1 year which is impressive, suggests long-term durability, and raises the option of watch-and-wait instead of planned local therapy. https://t.co/piy0iv…

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma https://t.co/e5QovkA82V

New #JITC article: Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis https://t.co/WfM3UFsvBq https://t.co/PjWUxAYqS4

Excited to see this new feature unveiled in #JITC. It's currently by EIC invitation only for certain accepted papers, but we are hoping to gather interest and momentum for future larger-scale use. I look forward to hearing what people think of this new …

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.